Latest news with #BrianAbrahams
Business Insider
2 days ago
- Business
- Business Insider
Vertex Pharmaceuticals (VRTX) Receives a Hold from RBC Capital
RBC Capital analyst Brian Abrahams reiterated a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target of $423.00. The company's shares opened today at $443.83. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Abrahams is an analyst with an average return of -1.9% and a 43.49% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Incyte, Neurocrine, and Sarepta Therapeutics. In addition to RBC Capital, Vertex Pharmaceuticals also received a Hold from Barclays's Gena Wang in a report issued on May 30. However, on June 3, Bank of America Securities maintained a Buy rating on Vertex Pharmaceuticals (NASDAQ: VRTX). Based on Vertex Pharmaceuticals' latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $2.77 billion and a net profit of $646.3 million. In comparison, last year the company earned a revenue of $2.69 billion and had a net profit of $1.1 billion
Yahoo
30-05-2025
- Business
- Yahoo
RBC Reaffirms Outperform on Regeneron (REGN) Ahead of Key COPD Drug Results
Analyst Brian Abrahams reiterated an Outperform rating and a price target of $943 for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on May 29. The rating comes as Regeneron awaits the findings of a phase III study on the medication candidate itepekimab, which is intended to treat chronic obstructive pulmonary disease (COPD). Based on a thorough analysis of preclinical and clinical data for COPD biologics, Abrahams expressed hope over itepekimab's potential to reduce episodes of COPD drastically. He estimates an unadjusted global peak revenue of $6 billion and believes that favorable study results could open up a sizable market opportunity. According to the analyst, there is a 65% possibility that Regeneron's stock would rise by 5–15% as a result of the upcoming itepekimab data. Additionally, he asserts that positive results from the itepekimab trials and other pipeline outcomes would divert investors' attention from worries about the depletion of Regeneron's other medicine, Eylea. While we acknowledge the potential of REGN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than REGN and that has 100x upside potential, check out our report about the cheapest AI stock. Read More: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
15-05-2025
- Business
- Yahoo
Neurocrine Biosciences, Inc. (NBIX): Among Billionaire Ken Griffin's Midcap Stock Picks with Huge Upside Potential
We recently published a list of . In this article, we are going to take a look at where Neurocrine Biosciences, Inc. (NASDAQ:NBIX) stands against Billionaire Ken Griffin's other midcap stock picks with huge upside potential. Ken Griffin, the founder of Citadel, is an influential albeit controversial figure in the investment industry. Ken Griffin tasted early success while trading during his college days, and it is safe to say that he has never looked back since. Despite huge setbacks during the financial crisis of 2008, he used his skills and determination to make a comeback where many others would have simply closed the fund and moved on. The billionaire investor currently manages assets worth around $65 billion across his funds. Owing to its large size and track record of success, Ken Griffin's stock moves often make it to the news and are closely followed by investors. We decided to do the same, focusing on Mid-cap stocks that still had the potential to turn into established giants tomorrow. To come up with the list of billionaire Ken Griffin's 10 midcap stock picks with huge upside potential, we looked at his latest 13F holdings and, among his significant holdings, only considered stocks between $10 billion and $40 billion in market cap. We then looked at the average analyst price target on Wall Street and ranked the stocks according to their upside potential. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here). A healthcare professional discussing treatment options for a patient with a neurological disorder. Stock Upside Potential: 45.88% Citadel Investment Group's Stake: $346,451,879 Neurocrine Biosciences, Inc. (NASDAQ:NBIX) operates as a developer, discoverer, and marketer of pharmaceuticals for neuroendocrine, neuropsychiatric, and neurological disorders. Its major product candidates include INGREZZA, Efmody capsules, Orilissa tablets, Oriahnn capsules, ALKINDI, and CRENESSITY. The firm was upgraded by RBC Capital Markets from Sector Perform to Outperform, highlighting the recent market downturn as an attractive buying opportunity. However, the price target was adjusted by RBC analyst Brian Abrahams from $138 to $137, anticipating short-term fluctuations due to the latest quarter earnings and long-term uncertainty surrounding Medicare drug price talks. RBC analysts think that the current share price is a good entry point for investors looking for a reliable biotech. RBC Capital Markets' analyst Brian Abrahams stated: Broader sector selloff and market downside has brought the stock to levels well below fundamental fair value, given an Ingrezza commercial franchise that we expect to be relatively solid and durable long term. Neurocrine Biosciences, Inc. (NASDAQ:NBIX) also reaffirmed its 2025 guidance after beating top-line estimates in the most recent quarter. Aided by ongoing direct-to-consumer initiatives and an expanded sales force, Neurocrine anticipates INGREZZA sales to reach $2.5 billion to $2.6 billion for the full year. Regardless of potential competition, this guidance demonstrates continued growth. Due to clinical adoption factors and delays in reimbursement processes, the company expects CRENESSITY's revenue to increase gradually. Moreover, Phase 3 trials for osavampator and NBI-568 are ongoing, with the firm setting aside $60 million to advance its product pipeline during 2025. Overall, NBIX ranks 4th on our list of Billionaire Ken Griffin's midcap stock picks with huge upside potential. While we acknowledge the potential of NBIX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than NBIX but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13-05-2025
- Business
- Yahoo
Neurocrine Biosciences, Inc. (NBIX): Among Billionaire Ken Griffin's Midcap Stock Picks with Huge Upside Potential
We recently published a list of . In this article, we are going to take a look at where Neurocrine Biosciences, Inc. (NASDAQ:NBIX) stands against Billionaire Ken Griffin's other midcap stock picks with huge upside potential. Ken Griffin, the founder of Citadel, is an influential albeit controversial figure in the investment industry. Ken Griffin tasted early success while trading during his college days, and it is safe to say that he has never looked back since. Despite huge setbacks during the financial crisis of 2008, he used his skills and determination to make a comeback where many others would have simply closed the fund and moved on. The billionaire investor currently manages assets worth around $65 billion across his funds. Owing to its large size and track record of success, Ken Griffin's stock moves often make it to the news and are closely followed by investors. We decided to do the same, focusing on Mid-cap stocks that still had the potential to turn into established giants tomorrow. To come up with the list of billionaire Ken Griffin's 10 midcap stock picks with huge upside potential, we looked at his latest 13F holdings and, among his significant holdings, only considered stocks between $10 billion and $40 billion in market cap. We then looked at the average analyst price target on Wall Street and ranked the stocks according to their upside potential. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here). A healthcare professional discussing treatment options for a patient with a neurological disorder. Stock Upside Potential: 45.88% Citadel Investment Group's Stake: $346,451,879 Neurocrine Biosciences, Inc. operates as a developer, discoverer, and marketer of pharmaceuticals for neuroendocrine, neuropsychiatric, and neurological disorders. Its major product candidates include INGREZZA, Efmody capsules, Orilissa tablets, Oriahnn capsules, ALKINDI, and CRENESSITY. The firm was upgraded by RBC Capital Markets from Sector Perform to Outperform, highlighting the recent market downturn as an attractive buying opportunity. However, the price target was adjusted by RBC analyst Brian Abrahams from $138 to $137, anticipating short-term fluctuations due to the latest quarter earnings and long-term uncertainty surrounding Medicare drug price talks. RBC analysts think that the current share price is a good entry point for investors looking for a reliable biotech. RBC Capital Markets' analyst Brian Abrahams stated: Broader sector selloff and market downside has brought the stock to levels well below fundamental fair value, given an Ingrezza commercial franchise that we expect to be relatively solid and durable long term. The company also reaffirmed its 2025 guidance after beating top-line estimates in the most recent quarter. Aided by ongoing direct-to-consumer initiatives and an expanded sales force, Neurocrine anticipates INGREZZA sales to reach $2.5 billion to $2.6 billion for the full year. Regardless of potential competition, this guidance demonstrates continued growth. Due to clinical adoption factors and delays in reimbursement processes, the company expects CRENESSITY's revenue to increase gradually. Moreover, Phase 3 trials for osavampator and NBI-568 are ongoing, with the firm setting aside $60 million to advance its product pipeline during 2025. Overall, NBIX ranks 4th on our list of Billionaire Ken Griffin's midcap stock picks with huge upside potential. While we acknowledge the potential of NBIX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than NBIX but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
31-03-2025
- Business
- Yahoo
Why Sarepta Therapeutics (SRPT) Stock Is Nosediving
Shares of biotech company Sarepta Therapeutics (NASDAQ:SRPT) fell 10.8% in the afternoon session after RBC analyst Brian Abrahams downgraded the stock from a Buy to a Hold rating and slashed the price target by nearly 50% to $87. The downgrade was driven by weaker-than-anticipated feedback from physicians regarding ELEVIDYS, suggesting that market reception for the treatment had fallen short. Notably, ELEVIDYS had been a big piece of Sarepta's growth story as it contributed more than 50% of sales in the Q4'2024 quarter. The shares closed the day at $63.77, down 9.4% from previous close. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Sarepta Therapeutics? Access our full analysis report here, it's free. Sarepta Therapeutics's shares are quite volatile and have had 16 moves greater than 5% over the last year. But moves this big are rare even for Sarepta Therapeutics and indicate this news significantly impacted the market's perception of the business. The previous big move we wrote about was 13 days ago when the stock dropped 24.9% on the news that the company reported the death of a Duchenne muscular dystrophy patient following treatment with its gene therapy, ELEVIDYS. The patient reportedly suffered acute liver failure, a known risk of AAV-mediated gene therapies. However, Sarepta suggested that a recent cytomegalovirus (CMV) infection might have worsened the condition. Despite this, the company maintained that ELEVIDYS still had a favorable benefit-risk profile. It planned to update the prescribing information and inform regulators, clinical investigators, and prescribing physicians of the incident. Markets were likely reacting negatively due to concerns that the event could increase regulatory scrutiny, make doctors more hesitant to prescribe the therapy, or slow adoption overall. Sarepta Therapeutics is down 48.6% since the beginning of the year, and at $63.75 per share, it is trading 61.1% below its 52-week high of $163.85 from June 2024. Investors who bought $1,000 worth of Sarepta Therapeutics's shares 5 years ago would now be looking at an investment worth $651.71. Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. We prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story. Sign in to access your portfolio
